Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

P 52: Interferon beta-a1 vs. Teriflunomide for Multiple Sclerosis

Multiple sclerosis (MS) is an inflammatory disorder, in which neurons in central nervous system (CNS) become demyelinated .MS is named for its formation of plaques due to sclerosis of myelin. Variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. It is commonly characterized by recurrent relapses and often followed by severe neurological disabi...

متن کامل

p 52: interferon beta-a1 vs. teriflunomide for multiple sclerosis

multiple sclerosis (ms) is an inflammatory disorder, in which neurons in central nervous system (cns) become demyelinated .ms is named for its formation of plaques due to sclerosis of myelin. variable degree of demyelination results in mild, mediate or severe symptomatic episodes of this disease. it is commonly characterized by recurrent relapses and often followed by severe neurological disabi...

متن کامل

Teriflunomide in Patients with Relapsing–Remitting Forms of Multiple Sclerosis

Teriflunomide is a once-daily oral agent that has been licensed in the EU since August 2013 for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS). More recently (September 2014), the EU summary of product characteristics (SmPC) was updated to include data from patients with a first clinical demyelinating event. This review examines the EU SmPC for teriflunomide,...

متن کامل

Injectable interferon beta-1b for the treatment of relapsing forms of multiple sclerosis

Multiple sclerosis (MS) is chronic inflammatory and demyelinating disease with either a progressive (10%-15%) or relapsing-remitting (85%-90%) course. The pathological hallmarks of MS are lesions of both white and grey matter in the central nervous system. The onset of the disease is usually around 30 years of age. The patients experience an acute focal neurologic dysfunction which is not chara...

متن کامل

Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis

Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies....

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Clinical Drug Investigation

سال: 2019

ISSN: 1173-2563,1179-1918

DOI: 10.1007/s40261-019-00750-3